BMO Capital analyst Etzer Darout initiated coverage of Kymera Therapeutics (KYMR) with a Market Perform rating and $55 price target Kymera is focused on targeted protein degradation to address previously intractable immune-inflammatory disease drug targets, the analyst tells investors in a research note. The firm believes the company’s pipeline has the ability to address diseases within biologically proven pathways, but is cautious on the risk/benefit profiles of its lead assets given the high bar for success. It needs to gain conviction on the company’s programs in 2025 given Kymera ‘s current valuation to recommend the shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- Kymera Therapeutics initiated with an Overweight at Stephens
- Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
- Kymera Therapeutics price target raised to $52 from $45 at Guggenheim
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says